Abstract
Melanomas are genetically heterogeneous, displaying mitogen-activated protein kinase mutations and homozygous loss of tumor suppressor genes. Mouse models combining such mutations produce fast-growing tumors. In contrast, rare, slow-growing tumors arise in mice combining Braf activation with heterozygous loss of Pten. Here we show that similar tumors can arise in albino mice bearing only a Braf mutation. Incidence kinetics suggest a stochastic event underlies tumorigenesis in tumors that arise with only a Braf mutation, yet de novo mutations or structural variants that could explain the incidence of most tumors could not be found. Single-cell transcriptomics of tumors identify a cell type resembling "neural crest-like" cells in human and mouse melanomas. These exist in normal skin, expand upon Braf activation, and persist through serial transplantation; analyses of gene expression suggest they serve as precursors of malignant cells. This state may serve as an intermediate on a slow path to malignancy that may provide a diagnostically and therapeutically important source of cellular heterogeneity.
Introduction
The prevailing "Vogelstein" model of cancer progression posits a linear accumulation of genetic mutations. In melanoma, activating BRAF mutations are known to initiate the process, yet they typically result in benign nevi (moles) that undergo growth arrest. The transition to malignancy is widely assumed to require a "second hit," such as the loss of the tumor suppressor PTEN. However, clinical observations of melanomas lacking obvious secondary mutations challenge this dogma. This study investigates the "minimal" pathway to melanoma: how cells with only a BRAF mutation can bypass senescence and transition to a tumor state.
Methods and Experimental Design
To explore this minimal pathway, researchers utilized specialized mouse models, specifically albino mice carrying a conditional Braf mutation (Braf CA/+). Unlike their black-furred counterparts, these albino mice occasionally develop slow-growing tumors even without secondary genetic drivers.
The team employed a multi-omic approach:
- Induction: Mutations were induced in neonatal mice (P2-P4) using topical application of 4-hydroxytamoxifen (4-OHT) to activate a Cre-recombinase system (Tyr::CreERT2).
- Genomic Analysis: Whole-genome sequencing (WGS) was performed on resulting tumors to identify potential de novo mutations or structural variants.
- Single-Cell Profiling: scRNA-seq was conducted on over 345,000 cells to map the transcriptomic landscape of tumor initiation.
- Functional Validation: The role of the transcription factor Sox2 was tested using conditional knockout models to determine its necessity in tumor formation.
Results
Stochasticity Over Mutation
One of the most striking findings was the lack of consistent secondary "driver" mutations in tumors arising from the minimal Braf CA/+ model. WGS and copy number variant (CNV) analysis failed to identify any recurrent genetic alterations that could explain the onset of malignancy across different tumors.
Instead, the timing of tumor appearance provided a critical clue. The tumor-free survival curves for albino Braf mice closely fit a "single-hit" exponential decay model. This kinetic evidence suggests that tumorigenesis in this context is triggered by a rare, stochastic (random) event—likely an epigenetic switch—rather than the accumulation of further DNA mutations.
The LNM Precursor State
Through scRNA-seq and trajectory inference, the researchers identified a unique cell population termed LNM (Lightly pigmented, Neural, extracellular Matrix). These cells exhibit a "neural crest-like" signature, resembling embryonic stem cells. The LNM state is not merely a byproduct of the tumor; these cells exist in normal skin, expand significantly upon Braf activation, and are predicted to be the direct precursors of malignant cells. In serial transplantation assays, the LNM population persisted and expanded, demonstrating its role as a robust intermediate state on the path to cancer.
Two Pathways to Melanoma
The study proposes two distinct routes to melanoma initiation:
- The "Fast Track": Driven by the homozygous loss of tumor suppressors (e.g., Pten), leading to rapid tumor growth.
- The "Slow Track": A stochastic transition from the Braf-activated LNM state to malignancy, bypassing the need for secondary mutations.
The Essential Role of Sox2
Functional experiments revealed that the transcription factor Sox2 is a mandatory requirement for the "slow path." While Sox2 is a known marker of stemness, its deletion specifically blocked tumor initiation in the Braf CA/+ Pten Δ/+ model, highlighting it as a potential therapeutic target for preventing progression in high-risk precursor lesions.
Discussion and Conclusion
This research identifies a persistent, neural-crest-like cell state that serves as a gateway to melanoma. The discovery that malignancy can arise through stochastic state transitions rather than just genetic accumulation has significant implications for how we understand tumor heterogeneity and drug resistance. The LNM state in mice aligns with similar neural crest-like states observed in human patients, particularly those who have developed resistance to BRAF-inhibitor therapies. Future work will focus on identifying the exact nature of the stochastic "switch" that triggers the final transition from the LNM state to a fully malignant tumor.
Summary updated